Pharmacotherapeutic management of paediatric heart failure and ACE-I use patterns: a European survey.
Cristina Castro DíezFeras KhalilHolger SchwenderMichiel DalinghausIda JovanovicNina MakowskiChristoph MaleMilica BajceticMarijke van der MeulenSaskia N de WildtLászló AblonczyAndrás SzatmáriIngrid KlingmannJennifer WalshStephanie LäerPublished in: BMJ paediatrics open (2019)
Despite some reluctance to use them in newborns, ACE-I seem key in paediatric HF treatment strategies. Use in single ventricle patients seems frequent, in apparent contradiction with current paediatric evidence. Disparate dosage criteria and potential formulation-induced variability suggest significant differences may exist in the risk-benefit profile children are exposed to. No uniformity seems to exist in the drug regimens in use. The information collected provides relevant insight into real-life clinical practice and may facilitate research to identify the best therapeutic options for HF children.
Keyphrases
- heart failure
- intensive care unit
- emergency department
- end stage renal disease
- young adults
- clinical practice
- newly diagnosed
- acute heart failure
- ejection fraction
- angiotensin ii
- pregnant women
- peritoneal dialysis
- drug delivery
- prognostic factors
- pulmonary hypertension
- drug induced
- cross sectional
- mitral valve
- pulmonary artery
- computed tomography
- magnetic resonance imaging
- pulmonary arterial hypertension
- magnetic resonance
- health information
- oxidative stress
- adverse drug
- cardiac resynchronization therapy
- contrast enhanced
- patient reported
- preterm birth